Quantum BioPharma announced that it has formally submitted an investigational new drug application to the FDA for Lucid-21-302, its new drug candidate for the treatment of multiple sclerosis.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNTM:
- Quantum BioPharma Taps Allucent for Phase 2 Trial of Novel MS Drug Lucid-MS
- Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial
- Quantum BioPharma Posts Strong 2025 Results, Extends Cash Runway and Advances MS and Alcohol Health Programs
- Quantum BioPharma Taps MS Expert to Lead Phase 2 Trial of Lucid-MS
- Is QNTM a Buy, Before Earnings?